WDYHV1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the WDYHV1 protein. This protein is a lesser-known but intriguing entity that plays a role in cellular processes through its unique sequence and domain structure. The WDYHV1 protein contains a conserved motif, represented by the sequence WDYHV, which is believed to be involved in protein-protein interactions or enzymatic regulation. Inhibitors targeting WDYHV1 focus on disrupting the function of this motif or other critical regions of the protein, thereby modulating its role in various biochemical pathways. Though the exact biological function of WDYHV1 is still under investigation, it is thought to participate in cellular regulation, possibly through interactions with other proteins or by influencing enzymatic activities that are important for maintaining cellular homeostasis.
The mechanism of action of WDYHV1 inhibitors involves binding to the WDYHV motif or other structurally significant regions of the protein, preventing it from carrying out its normal cellular functions. This inhibition can disrupt key interactions between WDYHV1 and other cellular components, leading to alterations in signaling pathways, protein stability, or enzymatic activities that rely on the presence of WDYHV1. Researchers utilize WDYHV1 inhibitors to explore the precise biological roles of this protein, offering insights into how it contributes to cellular processes such as protein regulation, intracellular signaling, or structural maintenance. By selectively blocking WDYHV1 activity, these inhibitors provide valuable tools for studying the impact of this protein on cellular function and its broader involvement in molecular networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can indirectly affect NTAN1 by modulating protein degradation pathways, potentially influencing proteins that interact with or are processed by NTAN1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132, another proteasome inhibitor, could impact the degradation pathways of proteins associated with NTAN1, indirectly influencing its function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a proteasome inhibitor that might indirectly affect NTAN1 by altering the degradation of proteins in pathways where NTAN1 is involved. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin, a specific proteasome inhibitor, could potentially affect proteins in pathways related to NTAN1's function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide affects the ubiquitin-proteasome system and might indirectly influence the function of NTAN1 by altering protein ubiquitination pathways. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide, a derivative of thalidomide, also impacts the ubiquitin-proteasome system, potentially affecting NTAN1 activity. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Pomalidomide, related to thalidomide and lenalidomide, may indirectly impact NTAN1 function through its effects on the ubiquitin-proteasome system. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, could indirectly affect NTAN1 by modulating signaling pathways that intersect with NTAN1's role in protein processing. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, might influence signaling pathways relevant to NTAN1's function, offering indirect modulation of its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, another PI3K inhibitor, may indirectly affect NTAN1 by altering PI3K/Akt signaling pathways. | ||||||